Itoh H, Yagi G, Tateyama M, Fujii Y, Iwamura K, Ichikawa K
Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(1):51-62. doi: 10.1016/0278-5846(84)90135-0.
Haloperidol serum levels were determined by the recently developed radioimmunoassay technique to elucidate the relationship between serum levels and clinical effects and that between serum levels and adverse effects. The serum levels of haloperidol in divided daily doses schedule reached to the steady state more rapidly (within 7 days) than in single dose schedule. The single daily dose schedule showed significantly wider diurnal variation than the divided daily doses schedule. No remarkable differences in serum concentration was noted between different types of oral haloperidol preparation (liquid, granule, tablet). No definite relationship was established between the serum concentration of haloperidol and incidence of tardive dyskinesia. No definite positive relationship between clinical effects and serum concentration of haloperidol could obtained.
采用最近开发的放射免疫分析技术测定了氟哌啶醇的血清水平,以阐明血清水平与临床疗效之间以及血清水平与不良反应之间的关系。每日分次给药方案中氟哌啶醇的血清水平比单次给药方案更快(7天内)达到稳态。每日单次给药方案的昼夜变化明显大于每日分次给药方案。不同类型的口服氟哌啶醇制剂(液体、颗粒、片剂)之间未观察到血清浓度有显著差异。氟哌啶醇的血清浓度与迟发性运动障碍的发生率之间未确立明确的关系。未获得氟哌啶醇的临床疗效与血清浓度之间明确的正相关关系。